Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc.; Thursday June 11, 4:38 pm EST
REMUNE is an immune-based therapy for the treatment of HIV infection which was discovered by Immune Response and is in phase III clinical trials. The two companies plan to complete development and apply for registration of REMUNE in 1999.
Under the agreement Immune Response will make commercial supplies of the drug and Agouron will have exclusive rights to market it in North America, Europe, as well as in certain other countries.
Immune Response may receive as much as $77 million over the next two years, including license and milestone payments of $45 million, payments to support development of $18 million, and the purchase of $14 million of Immune Response common stock at a premium to market, the company said in a statement.
The two companies will equally share all profits from the commercialization of REMUNE.
"We made the decision to aggressively pursue this opportunity with Immune Response after a comprehensive review of clinical data on REMUNE from a number of studies, which convinced us of the unique potential of this product to make a powerful contribution to the treatment of HIV infection and AIDS," said Agouron's President and Chief Executive Peter Johnson.
REMUNE is an immune-based therapy, derived from HIV itself, which has been shown to elicit an HIV-specific immune response.
980611
RE980606
Copyright © 1998 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .